To evaluate the safety and efficacy of 5 mg and 25 mg doses of mifepristone for the treatment of endometriosis.
Randomized double-blind study.
Eusebio Hern¨¢ndez Hospital, Havana, Cuba.
Twenty-six women laparoscopically diagnosed with endometriosis were included.
Group I received one tablet of 25 mg mifepristone daily and group II received one tablet of 5 mg mifepristone daily for 6 months. Laparoscopy and endometrial biopsy were performed before and after treatment.
Reduction in the intensity of dysmenorrhea measured by a visual analogue scale.
In both groups reductions in the intensity of dysmenorrhea and dyspareunia were highly significant compared with initial values (P <.001). All the women were amenorrheic after 45 days of treatment.
At doses of 5 mg or 25 mg, mifepristone could be an alternative for the treatment of endometriosis.